Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CAMP4 Therapeutics Corporation (Nasdaq: CAMP) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K and other registered offerings. CAMP4 identifies itself in these filings as a clinical-stage biopharmaceutical company developing regulatory RNA-targeting therapeutics and antisense oligonucleotide (ASO) drug candidates to upregulate gene expression for genetic diseases.
Through its Form 8-K filings, CAMP4 reports material events such as securities purchase agreements, private placements, and underwritten offerings of common stock registered on Form S-3. These filings describe how the company expects to use proceeds to support preclinical and clinical development of product candidates, including its SYNGAP1 program, and to fund working capital and general corporate purposes.
CAMP4’s 8-K filings also detail strategic collaboration agreements, including a research, collaboration and license agreement with GSK covering antisense oligonucleotide therapeutics targeting regulatory RNAs for neurodegenerative and kidney disease indications. The filings outline key terms such as exclusive worldwide licenses under certain patents and know-how, upfront payments, potential development and commercial milestones, and tiered royalties on net sales.
Additional 8-Ks address corporate governance and compensation matters, including changes to the board of directors, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and registration rights agreements associated with private placements. As an emerging growth company, CAMP4 uses these reports to communicate significant operational, financing, and collaboration developments.
On Stock Titan, investors can review CAMP4’s filings alongside AI-powered summaries that explain the significance of each document. Users can quickly see highlights from annual and quarterly reports when available, track current reports on Form 8-K, and monitor equity financing terms, collaboration structures, and other regulatory disclosures relevant to CAMP4’s RNA-targeting therapeutic pipeline.
Camp4 Therapeutics Corp received an amended Schedule 13G/A from investment entities affiliated with Vivo Opportunity, reporting significant passive ownership stakes in its common stock. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each beneficially own 3,856,991 shares, representing 7.4% of Camp4’s common stock based on 51,880,185 shares outstanding as of December 18, 2025. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each beneficially own 389,577 shares, or 0.8% of the same share base. The filing states that these securities are not held for the purpose of changing or influencing control of Camp4, but rather as passive investments.
FMR LLC and Abigail P. Johnson report a significant ownership stake in CAMP4 Therapeutics Corporation. As of the event date, they beneficially own 4,918,243 shares of CAMP4 common stock, representing 9.5% of the outstanding class.
FMR LLC has sole voting power over 4,916,914 shares and sole dispositive power over 4,918,243 shares, while Abigail P. Johnson is reported with sole dispositive power over the same 4,918,243 shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
CAMP4 Therapeutics Corporation reported that it has updated its corporate investor presentation as of January 2026. The company uses this presentation to provide the investment community with updates and summaries of its business. The refreshed materials are available in the Investors section of its website and have also been furnished as Exhibit 99.1 to this report under Regulation FD.
The company notes that the information in Item 7.01 and Exhibit 99.1 is being furnished, not filed, so it is not subject to certain liability provisions of the Exchange Act and is not automatically incorporated into other securities law filings unless specifically referenced.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 6,307,636 shares of CAMP4 Therapeutics Corp common stock, representing 12.2% of the class. The filing states that Janus Henderson Investors US LLC may be deemed the beneficial owner of these shares and also holds 1,241,382 pre-funded warrants that cannot be exercised if doing so would push ownership above 9.99%. All voting and dispositive power over the reported shares is shared, with no sole voting or dispositive power. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of CAMP4.
Janus Henderson Group plc filed a Schedule 13G reporting beneficial ownership of 6,307,636 shares of CAMP4 Therapeutics Corp common stock, representing 12.2% of the class. The filing states that Janus Henderson Investors US LLC may be deemed the beneficial owner of these shares and also holds 1,241,382 pre-funded warrants that cannot be exercised if doing so would push ownership above 9.99%. All voting and dispositive power over the reported shares is shared, with no sole voting or dispositive power. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of CAMP4.
CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC for a public offering of 5,000,000 shares of its common stock at $6.00 per share. All shares are being sold by the company, which estimates net proceeds of approximately $28.0 million after underwriting discounts, commissions, and expenses.
The shares are being issued under an effective Form S-3 shelf registration statement, with a related prospectus supplement filed on December 18, 2025. Closing of the offering is expected on or about December 19, 2025, subject to customary conditions. The company, its executive officers, directors, and certain stockholders agreed to a 60-day lock-up, while sales under the company’s at-the-market program may resume after 30 days from the underwriting agreement date.
CAMP4 Therapeutics Corporation entered into an underwriting agreement with Leerink Partners LLC for a public offering of 5,000,000 shares of its common stock at $6.00 per share. All shares are being sold by the company, which estimates net proceeds of approximately $28.0 million after underwriting discounts, commissions, and expenses.
The shares are being issued under an effective Form S-3 shelf registration statement, with a related prospectus supplement filed on December 18, 2025. Closing of the offering is expected on or about December 19, 2025, subject to customary conditions. The company, its executive officers, directors, and certain stockholders agreed to a 60-day lock-up, while sales under the company’s at-the-market program may resume after 30 days from the underwriting agreement date.
CAMP4 Therapeutics Corporation is offering 5,000,000 shares of its common stock at $6.00 per share, a primary offering that will provide approximately $28.0 million in net proceeds. The shares trade on the Nasdaq Global Market under the symbol “CAMP” and are expected to be delivered on or about December 19, 2025. After the deal, shares outstanding are expected to increase to 51,880,185, meaning existing holders are diluted but the company adds cash it plans to use mainly to advance its RNA-targeting drug pipeline and for general corporate purposes. New investors will see immediate dilution, as the as adjusted net tangible book value is estimated at $1.67 per share compared with the $6.00 purchase price.
CAMP4 Therapeutics Corporation is offering 5,000,000 shares of its common stock at $6.00 per share, a primary offering that will provide approximately $28.0 million in net proceeds. The shares trade on the Nasdaq Global Market under the symbol “CAMP” and are expected to be delivered on or about December 19, 2025. After the deal, shares outstanding are expected to increase to 51,880,185, meaning existing holders are diluted but the company adds cash it plans to use mainly to advance its RNA-targeting drug pipeline and for general corporate purposes. New investors will see immediate dilution, as the as adjusted net tangible book value is estimated at $1.67 per share compared with the $6.00 purchase price.
CAMP4 Therapeutics Corporation entered into a major Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to develop antisense oligonucleotide therapeutics for neurodegenerative and kidney disease targets. CAMP4 will use its regulatory RNA mapping and ASO discovery platform to identify and deliver lead ASO series for multiple collaboration targets, after which GSK assumes sole global responsibility for development, regulatory work, manufacturing, and commercialization.
Under the agreement, CAMP4 receives a one-time, non-refundable upfront payment of $17.5 million and is eligible for up to $440 million in development and commercial milestone payments if specified criteria are met, plus tiered royalties from low- to mid-single digits on annual net sales. The agreement includes customary governance, diligence, intellectual property, confidentiality, and indemnification provisions and can be terminated by GSK for convenience or by either party under specified circumstances.
CAMP4 Therapeutics Corporation entered into a major Research, Collaboration and License Agreement with GlaxoSmithKline Intellectual Property (No. 3) Limited to develop antisense oligonucleotide therapeutics for neurodegenerative and kidney disease targets. CAMP4 will use its regulatory RNA mapping and ASO discovery platform to identify and deliver lead ASO series for multiple collaboration targets, after which GSK assumes sole global responsibility for development, regulatory work, manufacturing, and commercialization.
Under the agreement, CAMP4 receives a one-time, non-refundable upfront payment of $17.5 million and is eligible for up to $440 million in development and commercial milestone payments if specified criteria are met, plus tiered royalties from low- to mid-single digits on annual net sales. The agreement includes customary governance, diligence, intellectual property, confidentiality, and indemnification provisions and can be terminated by GSK for convenience or by either party under specified circumstances.
CAMP4 Therapeutics is registering up to 33,431,131 shares of common stock for resale by existing investors, including 6,003,758 shares issuable upon exercise of pre-funded warrants. This total consists of 26,717,414 shares issued in a September 11, 2025 private placement (including the pre-funded warrant shares) and 6,713,717 additional shares with piggyback registration rights. The company will not receive proceeds from investor resales, but may receive cash if the 2025 pre-funded warrants, which have a $0.0001 per share exercise price, are exercised for cash.
The private placement raised approximately $50.1 million in gross proceeds at prices around $1.53 per share. As of October 1, 2025, CAMP4 had 46,880,185 shares of common stock outstanding. The prospectus notes that the registered resale shares represent about 69% of outstanding shares, so large sales could pressure the stock price.
CAMP4 is a clinical-stage biotech using its RNA Actuating Platform to upregulate gene expression for genetic diseases, with a lead preclinical program, CMP-002, for SYNGAP1-related neurodevelopmental disorders targeting a Phase 1/2 trial as early as the second half of 2026, and a clinical candidate CMP-001 for urea cycle disorders, where development spending is paused while the company seeks partners.
CAMP4 Therapeutics filed a shelf registration on Form S-3 to register up to $300,000,000 of common stock, preferred stock, warrants and debt securities, and added an at-the-market prospectus supplement to sell up to $100,000,000 of common stock from time to time.
Sales under the ATM will be made through Leerink Partners as sales agent under a Sales Agreement dated November 10, 2025, with a commission of up to 3.0% of gross proceeds. The company’s common stock trades on Nasdaq as “CAMP”; the last reported sale price was $4.25 on November 7, 2025. Net proceeds, if any, are intended for general corporate purposes, including R&D, clinical development, working capital and potential partnerships or in-licensing.
CAMP4 Therapeutics reported a Q3 net loss of $15.1 million as it advances RNA‑targeting programs and collaboration work. Revenue was $0.8 million in the quarter and $3.15 million year‑to‑date, driven by the BioMarin agreement and a Fulcrum milestone earlier in the year.
Cash and cash equivalents were $75.3 million at September 30, 2025, and management states this is sufficient to fund operations for at least the next twelve months. During September, the company completed an initial private placement closing, issuing 26,717,414 common shares and 6,003,758 pre‑funded warrants for $46.7 million in net cash proceeds. A related derivative tranche liability of $16.7 million was recorded, reflecting investors’ rights to a potential second closing subject to specified triggers.
R&D expense was $9.4 million in Q3 as CAMP4 progressed CMP‑002 toward GLP tox for SYNGAP1‑related disorders and paused new investment in CMP‑001 for urea cycle disorders while seeking partners. Shares outstanding were 46,880,185 at quarter‑end; 46,881,134 were outstanding as of November 3, 2025.